<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032058</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069254</org_study_id>
    <secondary_id>ACRIN-6659</secondary_id>
    <nct_id>NCT00032058</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer</brief_title>
  <official_title>MR Imaging And MR Spectroscopic Imaging Of Prostate Cancer Prior To Radical Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American College of Radiology Imaging Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures such as magnetic resonance imaging (MRI) and magnetic resonance&#xD;
      spectroscopic imaging (MRSI) may improve the ability to detect the extent of prostate cancer.&#xD;
      It is not yet known if MRI combined with MRSI is more effective than MRI alone in detecting&#xD;
      the extent of prostate cancer.&#xD;
&#xD;
      PURPOSE: Diagnostic trial to compare the effectiveness of combining MRI with MRSI to that of&#xD;
      MRI alone in determining the extent of prostate cancer in patients who are scheduled to&#xD;
      undergo surgery to remove the prostate gland.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the accuracy of MRI vs MRI combined with magnetic resonance spectroscopic&#xD;
           imaging (MRSI) for the localization of prostate cancer prior to radical prostatectomy in&#xD;
           patients with stage I or II adenocarcinoma of the prostate.&#xD;
&#xD;
        -  Compare the incremental benefit of these tests on diagnostic accuracy in these patients.&#xD;
&#xD;
        -  Compare the incremental benefit of MRSI for interobserver agreement vs MRI alone in the&#xD;
           localization of prostate cancer in these patients.&#xD;
&#xD;
        -  Compare the accuracy of combined MRSI with that of other available information on tumor&#xD;
           extent derived from digital rectal exam, PSA level, Gleason score, and Partin nomogram&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      At least 6 weeks after biopsy, patients undergo MRI and magnetic resonance spectroscopic&#xD;
      imaging (MRSI) over approximately 1 hour. Within 6 months of MRI/MRSI, patients undergo&#xD;
      radical prostatectomy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 134 patients will be accrued for this study within 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage I-II adenocarcinoma of the prostate&#xD;
&#xD;
               -  At least 6 weeks since prior biopsy&#xD;
&#xD;
          -  Scheduled to undergo radical prostatectomy within 6 months of MRI and magnetic&#xD;
             resonance spectroscopic imaging (MRSI)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac pacemakers&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Must be willing and able to undergo MRI/MRSI&#xD;
&#xD;
          -  No allergy to latex&#xD;
&#xD;
          -  No contraindications to MRI such as non-compatible intracranial vascular clips&#xD;
&#xD;
          -  No metallic hip implant or any other metallic implant or device that would compromise&#xD;
             quality of MRI/MRSI&#xD;
&#xD;
          -  No contraindications to or intolerance of endorectal coil insertion (e.g., prior&#xD;
             abdominoperineal resection of the rectum or Crohn's disease)&#xD;
&#xD;
          -  No general medical or psychiatric condition or physiologic status unrelated to&#xD;
             prostate cancer that would preclude valid informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior BCG for bladder cancer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior androgen-deprivation therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior prostatic or rectal radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior cryosurgery&#xD;
&#xD;
          -  No prior surgery for prostate cancer&#xD;
&#xD;
          -  No prior transurethral resection of the prostate (TURP)&#xD;
&#xD;
          -  No prior rectal surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior complementary alternative medicine&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Weinreb, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2005</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

